Abstract
Primary malignant central nervous system (CNS) tumors only represent about 2% of all cancers. However, they are very often associated with high morbidity and mortality. Despite current standard-of-care therapy, such as surgery, irradiation, and chemotherapy, neither cure nor any toxic therapy against malignant CNS tumors has been developed so far. Nanotechnology may alter this situation. It offers a new promise for cancer diagnosis and treatment. This emerging technology, by developing and manufacturing materials using atomic and molecular elements, can provide a platform for the combination of diagnostics, therapeutics and delivery to the tumor, with subsequent monitoring of the response. This review focuses on recent developments in cancer nanotechnology with particular attention to nanoparticle systems, important tools for the improvement of drug delivery in brain tumor. The latest advances in both the research sector and in recent patents for cancer imaging and therapy are discussed.
Keywords: Cancer treatment, drug delivery, gene therapy, nanotechnology, nanoparticle, patent, Glioma vasculature, Fluorescein, Magnetofluorescent nanoprobes, Liposomes, Gold NPs, Quantum dots, Magnetic nanocrystals, Dye-loaded NPs, Immunotargeted nanoshells, SPIONs, FITC, photoacoustic computed, omography (PAT), ZnCdS, EGFR, AS1411 aptamer, Chitosan, Hydrogels, PEGylated PHDCA, spinal neoplasm, LSFV-IL12, HSV-1-tk, EpCAM, MWCNTs, Nanostructure Enhanced X-ray Therapy, CAT scan, cGMP
Recent Patents on Anti-Cancer Drug Discovery
Title: Nanotechnology Advances in Brain Tumors: The State of the Art
Volume: 6 Issue: 1
Author(s): Gloria Invernici, Silvia Cristini, Giulio Alessandri, Stefania E. Navone, Laura Canzi, Daniela Tavian, Chiara Redaelli, Francesco Acerbi and Eugenio A. Parati
Affiliation:
Keywords: Cancer treatment, drug delivery, gene therapy, nanotechnology, nanoparticle, patent, Glioma vasculature, Fluorescein, Magnetofluorescent nanoprobes, Liposomes, Gold NPs, Quantum dots, Magnetic nanocrystals, Dye-loaded NPs, Immunotargeted nanoshells, SPIONs, FITC, photoacoustic computed, omography (PAT), ZnCdS, EGFR, AS1411 aptamer, Chitosan, Hydrogels, PEGylated PHDCA, spinal neoplasm, LSFV-IL12, HSV-1-tk, EpCAM, MWCNTs, Nanostructure Enhanced X-ray Therapy, CAT scan, cGMP
Abstract: Primary malignant central nervous system (CNS) tumors only represent about 2% of all cancers. However, they are very often associated with high morbidity and mortality. Despite current standard-of-care therapy, such as surgery, irradiation, and chemotherapy, neither cure nor any toxic therapy against malignant CNS tumors has been developed so far. Nanotechnology may alter this situation. It offers a new promise for cancer diagnosis and treatment. This emerging technology, by developing and manufacturing materials using atomic and molecular elements, can provide a platform for the combination of diagnostics, therapeutics and delivery to the tumor, with subsequent monitoring of the response. This review focuses on recent developments in cancer nanotechnology with particular attention to nanoparticle systems, important tools for the improvement of drug delivery in brain tumor. The latest advances in both the research sector and in recent patents for cancer imaging and therapy are discussed.
Export Options
About this article
Cite this article as:
Invernici Gloria, Cristini Silvia, Alessandri Giulio, E. Navone Stefania, Canzi Laura, Tavian Daniela, Redaelli Chiara, Acerbi Francesco and A. Parati Eugenio, Nanotechnology Advances in Brain Tumors: The State of the Art, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (1) . https://dx.doi.org/10.2174/157489211793979990
DOI https://dx.doi.org/10.2174/157489211793979990 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanotechnology, A Tool for Diagnostics and Treatment of Cancer
Current Topics in Medicinal Chemistry Medicinal Chemistry of 5-HT5A Receptor Ligands: A Receptor Subtype with Unique Therapeutical Potential
Current Topics in Medicinal Chemistry Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry STAT3 as a Therapeutic Target for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Potential Targets for Improving Radiosensitivity of Breast Tumor-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry LRRC4 Inhibits Glioma Cell Growth and Invasion Through a miR-185- Dependent Pathway
Current Cancer Drug Targets Recent Advances of MEK Inhibitors and Their Clinical Progress
Current Topics in Medicinal Chemistry Biomarkers for Systemic Therapy in Ovarian Cancer
Current Cancer Drug Targets Synthesis and SARs of Coumarin Fused 1,5-Benzothiazepines as Novel Anticancer and Antioxidant Agents
Mini-Reviews in Organic Chemistry Clinical Considerations of Focal Drug Delivery in Cancer Treatment
Current Drug Delivery Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Current Pharmaceutical Design Glioblastoma Multiforme Formation and EMT: Role of FoxM1 Transcription Factor
Current Pharmaceutical Design VEGF Signaling in Cancer Treatment
Current Pharmaceutical Design Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants
Current Neuropharmacology The Problem of Amino Acid Complementarity and Antisense Peptides
Current Protein & Peptide Science Combination of Salinomycin and AZD3463 Reveals Synergistic Effect on Reducing the Viability of T98G Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs as Potential Therapeutic Agents in the Treatment of Myocardial Infarction
Current Vascular Pharmacology Lipid Metabolism and Mitochondria: Cross Talk in Cancer
Current Drug Targets Glucose Transporters Regulation on Ischemic Brain: Possible Role as Therapeutic Target
Central Nervous System Agents in Medicinal Chemistry